Literature DB >> 17950356

Robotic Heller myotomy: a safe operation with higher postoperative quality-of-life indices.

L C Huffmanm1, P K Pandalai, B J Boulton, L James, S L Starnes, M F Reed, J A Howington, M S Nussbaum.   

Abstract

INTRODUCTION: Achalasia is a primary motility disorder of the esophagus that is treated most effectively with operative myotomy. Excellent outcomes with laparoscopic myotomy and fundoplication are well known. Heller myotomy utilizing a computer-enhanced (robotic) laparoscopic platform allows for a more precise dissection by utilizing the superior optics of a 3-dimensional camera and greater degrees of freedom provided by robotic instrumentation. How this affects outcome and quality of life is unknown.
METHODS: We assessed patients' health perceptions using a standardized, validated, health-related, disease-specific quality-of-life metric. Sixty-one consecutive patients undergoing laparoscopic or robotic myotomy over a 6-year period were evaluated prospectively. All operations were performed using intraoperative manometric and endoscopic guidance and all except 5 patients had a fundoplication. The effects of the operation on health-related quality of life were evaluated with the Short Form (SF-36) Health Status Questionnaire and a disease-specific gastroesophageal reflux disease activity (GERD) activity index (GRACI) preoperatively and postoperatively. All patients completed the questionnaire at both time points. Patient scores were compared using 2-way repeated measures analyses of variance followed by the Tukey test. Operative time, estimated blood loss, duration of stay, intraoperative complication, and postoperative complications were analyzed.
RESULTS: Thirty-seven patients had laparoscopic and 24 patients had robotic Heller myotomy. There was an increase in SF-36 overall evaluation of health postoperatively compared with preoperatively in both groups (P < .05). The robotic myotomy patients had better SF-36 Role Functioning (emotional) and General Health Perceptions (P < .05) compared with the laparoscopic group. The GRACI showed an equivalent improvement in severity of symptoms in both groups (P < .05). Operative time was 287 +/- 9 minutes for laparoscopic cases and 355 +/- 23 minutes for robotic cases. Estimated blood loss and duration of stay were not different between groups. There were 3 operative esophageal perforations (8%) during laparoscopic myotomy and all were repaired immediately. There were no perforations or operative complications in the robotic group. Neither group had any additional complications.
CONCLUSIONS: Minimally invasive operative myotomy improves functional status and overall evaluation of health in patients with achalasia. Robotic myotomy had no intraoperative esophageal perforations compared with an 8% intraoperative rate during laparoscopic myotomy. Heller myotomy with partial fundoplication using a robotic platform appears to be a more precise and safer operation than laparoscopic myotomy with improved quality-of-life indices postoperatively compared with laparoscopic myotomy with fewer complications; this suggests that, in skilled hands, the robotic platform may be safer, with improved quality-of-life outcomes.

Entities:  

Mesh:

Year:  2007        PMID: 17950356     DOI: 10.1016/j.surg.2007.08.003

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  30 in total

1.  SAGES guidelines for the surgical treatment of esophageal achalasia.

Authors:  Dimitrios Stefanidis; William Richardson; Timothy M Farrell; Geoffrey P Kohn; Vedra Augenstein; Robert D Fanelli
Journal:  Surg Endosc       Date:  2011-11-02       Impact factor: 4.584

Review 2.  Robotic-assisted Heller myotomy: a modern technique and review of outcomes.

Authors:  Cheguevara Afaneh; Brendan Finnerty; Jonathan S Abelson; Rasa Zarnegar
Journal:  J Robot Surg       Date:  2015-03-21

Review 3.  Robotic general surgery: current practice, evidence, and perspective.

Authors:  M Jung; P Morel; L Buehler; N C Buchs; M E Hagen
Journal:  Langenbecks Arch Surg       Date:  2015-02-18       Impact factor: 3.445

Review 4.  Endoscopic and Surgical Treatments for Achalasia: Who to Treat and How?

Authors:  Romulo A Fajardo; Roman V Petrov; Charles T Bakhos; Abbas E Abbas
Journal:  Gastroenterol Clin North Am       Date:  2020-06-26       Impact factor: 3.806

5.  The first nationwide evaluation of robotic general surgery: a regionalized, small but safe start.

Authors:  Blair A Wormer; Kristian T Dacey; Kristopher B Williams; Joel F Bradley; Amanda L Walters; Vedra A Augenstein; Dimitrios Stefanidis; B Todd Heniford
Journal:  Surg Endosc       Date:  2013-11-07       Impact factor: 4.584

6.  Robotic-assisted Heller myotomy for esophageal achalasia: feasibility, technique, and short-term outcomes.

Authors:  Carlos A Galvani; Alberto S Gallo; Mark R Dylewski
Journal:  J Robot Surg       Date:  2011-02-19

7.  Role of robotic-assisted surgery in benign esophageal diseases.

Authors:  Shireesh Saurabh; Eric Unger; Julie Grossman; Francisco Couto; Namrata Singh; David Scott Lind; Lucian Panait; Andres Castellanos
Journal:  J Robot Surg       Date:  2013-08-15

8.  Robot-assisted gastroesophageal surgery: usefulness and limitations.

Authors:  Ismael Diez Del Val; Cándido Martinez Blazquez; Carlos Loureiro Gonzalez; Jose Maria Vitores Lopez; Valentin Sierra Esteban; Julen Barrenetxea Asua; Izaskun Del Hoyo Aretxabala; Patricia Perez de Villarreal; Jose Esteban Bilbao Axpe; Jaime Jesus Mendez Martin
Journal:  J Robot Surg       Date:  2013-09-14

Review 9.  Major complications of pneumatic dilation and Heller myotomy for achalasia: single-center experience and systematic review of the literature.

Authors:  Kristle L Lynch; John E Pandolfino; Colin W Howden; Peter J Kahrilas
Journal:  Am J Gastroenterol       Date:  2012-10-02       Impact factor: 10.864

10.  Robotic heller myotomy and Dor fundoplication for achalasia in a woman with morbid obesity.

Authors:  Abdulkadir Bedirli; Ibrahim Dogan; Ramazan Kozan
Journal:  J Robot Surg       Date:  2012-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.